Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice

Journal of Immunology

Volumn 182, Issue 5, 2009, Pages 3063-3071

  Poon, Leo L M ^a   Leung, Y H Connie ^a   Nicholls, John M ^a   Perera, Pin Yu ^b   Lichy, Jack H ^b   Yamamoto, Masafumi ^c   Waldmann, Thomas A ^d   Peiris, J S Malik ^a   Perera, Liyanage P ^d  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NIHON UNIVERSITY   (Japan)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 15; MATRIX PROTEIN; MATRIX PROTEIN M1; MATRIX PROTEIN M2; NEUTRALIZING ANTIBODY; NUCLEOPROTEIN; UNCLASSIFIED DRUG; VIRUS SIALIDASE; DISINFECTANT AGENT; LIVE VACCINE; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CLADISTICS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; INFLUENZA; INFLUENZA VIRUS A H5N1; LETHALITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINATION; VACCINE PRODUCTION; VACCINIA VIRUS; VIRUS RECOMBINANT; VIRUS TITRATION; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CLASSIFICATION; DOG; EPIDEMIC; GENE VECTOR; GENETICS; IMMUNOLOGY; ORTHOMYXOVIRUS INFECTION; VALIDATION STUDY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL LINE; DISEASE OUTBREAKS; DISINFECTANTS; DOGS; FEMALE; GENETIC VECTORS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INTERLEUKIN-15; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 64849110995     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803467     Document Type: Article

References (27)

1. Hilleman, M. R. 2002. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine 20: 3068-3087.
2. Webster, R. G., and E. A. Govorkova. 2006. H5N1 influenza-continuing evolution and spread. N. Eng. J. Med. 355: 2174-2177.
3. El Sahly, H. M., and W. A. Keitel. 2008. Pandemic H5N1 influenza vaccine development: an update. Expert Rev. Vaccines 7: 241-247.
4. Ausubel, F. M., R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl, eds. 2005. Current Protocols in Molecular Biology. John Wiley and Sons, New York.
5. Perera, L. P., C. K. Goldman, and T. A. Waldmann. 2001. Comparative assessment of virulence of recombinant vaccinia viruses expressing IL-2 and IL-15 in immunodeficient mice. Proc. Natl. Acad. Sci. USA 98: 5146-5151.
6. Gong, J. H., G. Maki, and H. G. Klingemann. 1994. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658.
7. Oh, S., J. A. Berzofsky, D. S. Burke, T. A. Waldmann, and L. P. Perera. 2003. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc. Natl. Acad. Sci. USA 100: 3392-3397.
8. Fan, J., X. Liang, M. S. Horton, H. C. Perry, M. P. Citron, G. J. Heidecker, T. M. Fu, J. Joyce, C. T. Przysiecki, P. M. Keller, et al. 2004. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22: 2993-3003.
9. Perera, L. P., T. A. Waldmann, J. D. Mosca, N. Baldwin, J. A. Berzofsky, and S. K. Oh. 2007. Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice. J. Virol. 81: 8774-8783.
10. Eichelberger, M., H. Golding, M. Hess, J. Weir, K. Subbarao, C. J. Luke, M. Friede, and D. Wood. 2008. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development. Bethesda, Maryland, U.S., December 10-11, 2007. Vaccine 26: 4299-4303.
11. Gómez, C. E., J. L. Nájera, M. Krupa, and M. Esteban. 2008. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr. Gene Ther. 8: 97-120.
12. Fenner, F., D. A. Henderson, I. Arita, Z. Jezek, and I. D. Ladnyi. 1988. Smallpox and Its Eradication. World Health Organization, Geneva, Switzerland.
13. Altstein, A. D., A. K. Gitelman, Y. A. Smirnov, L. M. Piskareva, L. G. Zakharova, G. V. Pashvykina, M. M. Shmarov, O. P. Zhirnov, N. P. Varich, P. O. Ilyinskii, and A. M. Shneider. 2006. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Arch. Virol. 151: 921-931.
14. Jakeman, K. J., H. Smith, and C. Sweet. 1989. Mechanism of immunity to influenza: maternal and passive neonatal protection following immunization of adult ferrets with a live vaccinia-influenza virus haemagglutinin recombinant but not with recombinants containing other influenza virus proteins. J. Gen. Virol. 70: 1523-1531.
15. Bermejo-Martin, J. F., D. J. Kelvin, Y. Guan, H. Chen, P. Perez-Breña, I. Casas, E. Arranz, and R. O. de Lejarazu. 2007. Neuraminidase antibodies and H5N1: geographic-dependent influenza epidemiology could determine cross-protection against emerging strains. PLoS Med. 4: e212.
16. Jameson, J., J. Cruz, and F. A. Ennis. 1998. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J. Virol. 72: 8682-8689.
17. Lee, L. Y., L. A. do Ha, C. Simmons, M. D. de Jong, N. V. Chau, R. Schumacher, Y. C. Peng, A. J. McMichael, J. J. Farrar, G. L. Smith, et al. 2008. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J. Clin. Invest. 118: 3478-3490.
18. Waldmann, T. A. 2006. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6: 595-601.
19. + T cells. Proc. Natl. Acad. Sci. USA 101: 15154-15159.
20. Yee, C., P. A. Savage, P. P. Lee, M. M. Davis, and P. D. Greenberg. 1999. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162: 2227-2234.
21. Gallimore, A., T. Dumrese, H. Hengartner, R. M. Zinkernagel, and H. G. Rammensee. 1998. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J. Exp. Med. 187: 1647-1657.
22. Bernasconi, N. L., E. Traggiai, and A. Lanzavecchia. 2002. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298: 2199-2202.
23. Suguitan, A. L., Jr., J. McAuliffe, K. L. Mills, H. Jin, G. Duke, B. Lu, C. J. Luke, B. Murphy, D. E. Swayne, G. Kemble, and K. Subbarao. 2006. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med. 3: e360.
24. Hoelscher, M. A., S. Garg, D. S. Bangari, J. A. Belser, X. Lu, I. Stephenson, R. A. Bright, J. M. Katz, S. K. Mittal, and S. Sambhara. 2006. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367: 475-481.
25. Kreijtz, J. H., Y. Suezer, G. van Amerongen, G. de Mutsert, B. S. Schnierle, J. M. Wood, T. Kuiken, R. A. Fouchier, J. Lower, A. D. Osterhaus, et al. 2007. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J. Infect. Dis. 195: 1598-1606.
26. Lu, X., L. E. Edwards, J. A. Desheva, D. C. Nguyen, A. Rekstin, I. Stephenson, K. Szretter, N. J. Cox, L. G. Rudenko, A. Klimov, and J. M. Katz. 2006. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 24: 6588-6593.
27. Stephenson, I., K. G. Nicholson, K. Hoschler, M. C. Zambon, K. Hancock, J. DeVos, J. M. Katz, M. Praus, and A. Banzhoff. 2008. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N. Engl. J. Med. 359: 1631-1633.